Nosheng Medical Submits IPO Prospectus for Its High-Frequency Composite Pulsed Electric Field Ablation System G1 – An Optimized Solution for Focal Therapy of Prostate Cancer

With advancements in medical care, an increasing number of patients with low- to intermediate-risk prostate cancer are being diagnosed. Among those undergoing radical prostatectomy, 30% experience lifelong urinary incontinence, and 80% suffer loss of sexual function. Irreversible electroporation technology, throughPrecise Focal Localization, enabling precise tumor ablation while better preserving patients' urinary continence and sexual function, thereby extending life with improved quality.

Globally, Nuosheng Medical pioneered the application of high-frequency irreversible electroporation technology for the treatment of prostate cancer. The G1 composite steep-pulse therapy device enables individualized configuration of each polar pulse width, utilizes electrodes with insulated distal tips, and employs optimized needle placement strategies. This approach effectively eradicates prostate cancer cells while preserving patients’ sexual and urinary continence functions. The product has obtained Class III medical device certification from the National Medical Products Administration and is currently in clinical use at multiple hospitals across China.

Artery Select New Product Review, Issue 10, featuringProfessor Dong Bojun, Chief Physician of the Department of Urology at Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Dr. Luo Zhongbao, CTO of the R&D Department at Nuosheng Medical, delivered an impressive presentation on Nuosheng Medical’s high-frequency composite steep pulse therapy device.

Complete Ablation:The ablation zone has well-defined borders, with a nearly 100% apoptosis rate within the area.

Preservation of Urinary Continence:Unique tissue selectivity effectively avoids injury to the urethra and urinary continence nerves, thereby preserving urinary continence function.

Preservation of Sexual Function:No significant damage to surrounding functional vascular and neural structures, enabling more precise preservation of sexual function.

Easy-to-Perform Ultra-Minimally Invasive Therapy:Personalized electrode needle settings cause damage to normal tissue limited to only a few 1-mm puncture sites; the procedure is simple, with short operative time and minimal bleeding and complications.

This event has invitedDr. Luo Zhongbao, CTO of the R&D Department at Nuosheng MedicalCorporate Introduction,Professor Dong Bojun, Chief Physician of the Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineAdvantages of Irreversible Electroporation in Focal Therapy for Prostate Cancer and Clinical Case Sharing

Viewing Options: Scan the QR code on the poster below to add our assistant and reserve your spot for the live broadcast.

Prof. Dong Bojun
Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine | Chief Physician

Ph.D., Supervisor of Graduate Students; Postdoctoral Fellow at The University of Texas MD Anderson Cancer Center; Member of the Prostate Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO); Member of the Basic Research Group, Urology Branch, Chinese Medical Association; Deputy Secretary-General, Geriatric Urology Branch, Chinese Geriatrics Society; Member of the Prostate Cancer Group, Professional Committee on Genitourinary Malignancies, China Anti-Cancer Association; Standing Committee Member, Multidisciplinary Tumor Diagnosis Collaboration Group, Professional Committee on Tumor Markers, China Anti-Cancer Association; Corresponding Editorial Board Member, *Chinese Journal of Urology*. Primarily engaged in the clinical diagnosis, treatment, and research of urological tumors, with a special focus on prostate cancer.

Dr. Luo Zhongbao
R&D Department, Shanghai Nuosheng Medical Technology Co., Ltd. | CTO

Ph.D. in Engineering from Harbin Institute of Technology; Standing Committee Member of the Product Reliability Professional Committee, China Association for Medical Device Industry; Member of the Shanghai Young Scientists Association.

Specializing in the R&D and industrialization of mechatronic medical devices, with a focus on areas such as tumor ablation equipment and medical robots. During his doctoral studies and professional career, he published over 10 related papers, filed 70 patent applications, and completed four research projects funded by Shanghai Municipality and Pudong New Area. In 2022, he was consecutively honored with titles including “Talent in Key Industrial Sectors of Shanghai” and “Industrial Youth Elite under Shanghai’s High-Level Industrial Talent Development Program.”

Shanghai Nuosheng Medical Technology Co., Ltd. (“Nuosheng Medical”) was established in September 2016. Its main product is a composite steep pulse therapy device based on the principle of irreversible electroporation, for which the company holds full independent intellectual property rights. On April 1, 2021, Nuosheng Medical’s composite steep pulse therapy device for prostate tumor ablation treatment officially received the Class III medical device registration certificate issued by the National Medical Products Administration (NMPA), and obtained its production license on April 30.

The company’s production and R&D base is located in Zhangjiang Med Valley, Shanghai. It features Class 10,000 cleanrooms designed in accordance with GMP standards, high-standard assembly workshops, and comprehensive testing laboratories. The company has obtained ISO 13485 quality management system certification and is currently applying for EU CE certification. Its professional team comprises over 100 experts and talents across various fields, including R&D, medical affairs, production, sales, clinical operations, regulatory affairs, and quality assurance.

“Artery Select New Product Debut” is a live-streaming program under “Artery Select” that supports medical enterprises in launching innovative products. The program’s mission is to empower the milestone launch of every innovative medical product.

Scan the QR Code to Join the Group and Reserve a Spot for the Live Stream

(Already added; please inquire proactively)